Cizutamig for moderate to severe ulcerative colitis
Treatments studied
Part of Digestive system clinical trials.
This trial tests a new drug called cizutamig for people with moderate to severe ulcerative colitis who have already tried other advanced treatments. The goal is to see if cizutamig can reduce inflammation and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with moderate to severe ulcerative colitis (UC) that affects more than just the rectum.
- You have tried at least one biologic or advanced therapy (like a TNF blocker or tofacitinib) and it either didn't work or caused side effects.
- You are willing to stay on your current UC medications, if any, without changing them.
- You have had a recent colonoscopy (within the last year) if you've had UC for many years, or if you have other risk factors for colon cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental tablet for people with moderate to severe ulcerative colitis that hasn't improved with standard treatments. It aims to see if the tablet can reduce symptoms and inflammation.
This study tests a new drug called XmAb942 for people with moderate to severe ulcerative colitis. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments haven't worked well enough or caused side effects.
This trial tests if starting with the stronger drug mirikizumab (top-down therapy) works better than the usual treatment with azathioprine for people newly diagnosed with moderate-to-severe ulcerative colitis. It aims to see which approach controls inflammation and improves symptoms faster.
This trial tests an investigational drug called cizutamig for people with generalized myasthenia gravis (gMG) whose symptoms are not well controlled by current treatments. The goal is to see if it can improve daily activities.
This study tests a new drug called cizutamig for thyroid eye disease (TED), a condition where the eye muscles and tissues swell due to Graves' disease. The drug is designed to reduce inflammation and may help improve symptoms like eye bulging, double vision, and discomfort.
This trial tests an experimental drug called Cizutamig to see if it can help people with systemic sclerosis (SSc), a condition that causes skin thickening and organ problems. You may qualify if you have had SSc for 7 years or less and your skin score is at least 15.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.